Treatment of Acute Myeloid Leukemia With Arsenic and All-trans Retinoid Acid
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
The clinical trial was designed to prove that Arsenic plus ATRA possibly had an effect on
improving the symptoms, reducing the early mortality rate and prolonging the total survival
time of patients with newly diagnosed or relapsed AML.
Phase:
Phase 1
Details
Lead Sponsor:
First Affiliated Hospital Xi'an Jiaotong University